Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Researchers are trying to develop ways to more quickly and accurately diagnose Alzheimer’s, which might lead to better treatments and understanding in the future Via Krishan Maggon 
No comment yet.
Sign up to comment
Scoop.it!
Alzheimer’s disease (AD) is the most common form of dementia, afflicting more than 30 million people worldwide. Currently, there is no cure or way to prevent this devastating disease. Via Krishan Maggon
Gilbert C FAURE's insight:
Abstract
.... Extracellular plaques, containing various forms of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein, are two major pathological hallmarks of the AD brain. Aggregation, deposition, and N-terminal modification of Aβ protein and tau phosphorylation and aggregation are thought to precede the onset of cognitive decline, which is better correlated with tangle formation and neuron loss. Active and passive vaccines against various forms of Aβ have shown promise in pre-clinical animal models. However, translating these results safely and effectively into humans has been challenging. Recent clinical trials showed little or no cognitive efficacy, possibly due to the fact that the aforementioned neurodegenerative processes most likely pre-existed in the patients well before the start of immunotherapy. Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease. In addition, efforts to immunize against tau and other AD-related targets are underway.
Krishan Maggon 's curator insight,
November 2, 2014 1:56 AM
Review Immunotherapy for Alzheimer’s disease: hoops and hurdlesCynthia A Lemere Correspondence: Cynthia A Lemere clemere@partners.org Author Affiliations Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, NRB 636F, 77 Avenue Louis Pasteur, Boston 02115, MA, USA Molecular Neurodegeneration 2013, 8:36 doi:10.1186/1750-1326-8-36 The electronic version of this article is the complete one and can be found online at:http://www.molecularneurodegeneration.com/content/8/1/36 Received:3 July 2013Accepted:23 September 2013Published:22 October 2013 © 2013 Lemere; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Scoop.it!
The amyloid precursor protein (APP) is mainly known for being the precursor of the ß-amyloid peptide, which accumulates in plaques found in the brain of Alzheimer's disease patients. Via Krishan Maggon
Krishan Maggon 's curator insight,
November 16, 2014 3:21 AM
Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century*Franco R , Navarro G, Martínez-Pinilla E and Moreno E JOURNAL OF NEUROLOGY AND NEUROLOGICAL DISORDERS
Copyright: © 2014 Franco R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
